References
- Teng, TO, Adams ME, Pliskin JS et al Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 15, 369–390 (1995).
- •Compiled cost-effectiveness ratios.
- Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 276,1253–1258 (1996).
- •The second in a three-part series, describing the basis for recommendations: reference case analysis, measurements, decisions processes and handling uncertainty.
- Stone PW, Teutsch S, Chapman RH et al Cost-utility analyses of clinical preventive services published ratios, 1976–1997. Am. J. Prey Med. 19,15-23 (2000).
- •Of 50 analyses cited, immunizations and chemoprophylmds were found to have the most favorable cost-effectiveness ratios.
- De Wals P, Erickson L. Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec. Vaccine 20,2840–2844 (2002).
- Lieu TA, Ray GT, Black SB et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 283, 1460–1468 (2000).
- Jacobs RJ, Meyerhoff AS. Comparative cost-effectiveness of varicella, hepatitis A and pneumococcal conjugate vaccines. Prey Med. 33,639–645 (2001).
- McIntosh EDG, Fletcher MA, Fritzell B. Burden of invasive pneumococcal disease (IPD) in Europe. 4th International Symposium on Pneumococci and Pneumococcal Diseases OPPD-4). Helsinki, Finland. 9–13 May (2004).
- Black S, Shinefield H, Fireman B et al Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatl: Infect. Dis. J. 19,187-195 (2000).
- ••The landmark vaccine efficacy trialforming the basis for all the cost-effectiveness analyses.
- Ray GT, Butler JC, Black SB etal. Observed costs and healthcare use of children in a randomized controlled trial of pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 21,361–365 (2002).
- Whitney CG, Farley MM, Hadler J et al Decline in invasive pneumococcal disease after introduction of protein—polysaccharide conjugate vaccine. N Engl. J. Med. 348, 1737–1746 (2003).
- ••Provides the basis for the added benefit ofprotection of adults through vaccination of infants and children.
- Lebel MH, Kellner JD, Ford-Jones EL et al A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clin. Infect. Dis. 36,259-268 (2003).
- Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med. Decis. Making13,322–338 (1993).
- De Wals P, Petit G, Erickson LJ et al Benefits and costs of immunization with pneumococcal conjugate vaccine in Canada. Vaccine 21,3757–3764 (2003).
- Moore D, Bigham M, Patrick D. Modeling the costs and effects of a universal infants immunization program using conjugated pneumococcal vaccine in British Columbia. CCDR 29,97–104 (2003).
- Ess SM, Schaad UB, Gervaix A, Pinösch A, Szucs T. Cost-effectiveness of a pneumococcal conjugate immunization program for infants in Switzerland. Vaccine 21,3273–3281 (2003).
- Ruedin HJ, Ess S, Zimmermann HP, Szucs T. Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies. Vaccine 21,4145–4152 (2003).
- Claes C, Graf von der Schulenburg J-M. Cost-effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany. Pharmacoeconomics 21,587–600 (2003).
- Berg S, Sorberg M, Prellner K et al Economic evaluation of heptavalent pneumococcal conjugate vaccine in Sweden. 21st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Sicily, Italy, 9–11 April (2003).
- Salo H, Sintonen H, Kilpi T et al Economic evaluation of pneumococcal vaccination program in Finland. 21st Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Sicily, Italy, 9–11 April (2003).
- Asensi F, De Jose M, Lorente M et al A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value in Health 7,36–51 (2004).
- Perez Mendez C, Solis Sanchez G, Miguel Martinez D et al Predictive factors for invasive pneumococcal disease: a case-control study. An. Esp. Pediatr. 57,310–316 (2002).
- Bos JM, Rtimke H, Welte R et al. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. Vaccine 20, 202–207 (2001).
- Bos JM, Rtimke H, Welte R, Postma MJ. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in The Netherlands. Clin. Ther 25,2614–2630 (2003).
- Zwart-van Rijkom JE, Leufkens HG, Busschbach JJ et al Differences in attitudes, knowledge and use of economic evaluations in decision-making in The Netherlands. The Dutch results from the EUROMET Project. Pharmacoeconomics 18,149–160 (2000).
- Stouthard MEA, Esselink-Bot ML, van Bonsel G et al. Weighing Factors for Diseases in The Netherlands. Amsterdam, The Netherlands: Institute for Social Healthcare, Amsterdam Medical Center (1997).
- Miller E, Waight P, Efstratiou A etal. Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996–1998. Acta Pediatr. 435 (Suppl.), 11–16 (2000).
- McIntosh EDG, Conway P, Willingham J, Lloyd A. The cost burden of pediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine 21,2564–2572 (2003).
- Whitney C. Effect of pneumococcal conjugate vaccine on invasive disease in the US. 4th International Symposium on Pneumococci and Pneumococcal Diseases 7SPPD-4). Helsinki, Finland. 9–13 May (2004).
- Melegaro A, Edmunds WJ. Cost- effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine (In Press).
- Hanna JN, Gratten M, Tiley SM, Brookes DL, Bapty G. Pneumococcal vaccination: an important strategy to prevent pneumonia in Aboriginal and Torres Strait Island adults. Aust. NZ J Public Health 21, 281–285 (1997).
- Torzillo P, Dixon J, Manning K et al Etiology of acute lower respiratory tract infection in Central Australian Aboriginal children. PediaM Infect. Dis. J. 18,714–721 (1999).
- Butler JRG, McIntyre P, MacIntyre CR et al. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine 22,1138–1149 (2004).
- Sinha A, Lee G, Ginsberg G et al. Pneumococcal vaccination of infants in the developing world: A cost-effectiveness analysis. 4th International Symposium on Pneumococci and Pneumococcal Diseases OPPD-4). Helsinki, Finland. 9–13 May (2004).
Websites
- National Institute for Clinical Excellence. Guide to Methods of Technology Appraisal (Ref N0515) www.nice.org.uldpdf/TAP_Methods.pdf Accessed July, 2004 Affiliations.